Objective: Hepatic energy metabolism negatively relates to insulin resistance and liver fat content in patients with type 2 diabetes, but its role in metabolically healthy humans is unclear. We hypothesized that intrahepatocellular g-adenosine triphosphate (gATP) and inorganic phosphate (P i ) concentrations exhibit similar associations with insulin sensitivity in nondiabetic, nonobese volunteers.
obese individuals without nonalcoholic steatohepatitis exhibit increased hepatic oxidative capacity (1) . These conflicting results may result from adaptive upregulation of oxidative phosphorylation in obesity (1) , along with enhanced production of reactive oxygen species. Increased reactive oxygen species production, which is also linked to hyperglycemia and hyperlipidemia, can induce mitochondrial damage and thereby, contribute to lower mitochondrial function in T2D and nonalcoholic steatohepatitis (1, 3, 4) .
In exercising skeletal muscle, ATP production is mainly regulated by training intensity, whereas in the liver, ATP-consuming metabolic processes challenge hepatic mitochondria (5, 6) . Several factors, such as body mass index (BMI), glycemia, and hepatic insulin sensitivity (1, 2, 7), affect skeletal muscle and hepatic phosphorus metabolites in metabolic diseases, but there are no data on the factors regulating energy metabolism in nonobese nondiabetic persons. Cellular metabolic processes require substrate supply and signaling, particularly by branched-chain amino acids (BCAAs) (8, 9) and nonesterified fatty acids (NEFAs) (10) . Although BCAAs have been suggested to improve energy metabolism (8) , BCAAs are also increased in insulin-resistant states, such as obesity and T2D, and can induce insulin resistance (8, 9) . In metabolic diseases, impaired BCAA metabolism could lead to accumulation of toxic BCAA metabolites, which would, in turn, impair mitochondrial function and give rise to stress signaling associated with insulin resistance (8) . Likewise, chronic increases in NEFA can also induce insulin resistance (4) and have been linked to abnormal mitochondrial function (4) . Although BCAA and NEFA likely reflect the risk for metabolic diseases (4, 8) , their physiological roles for hepatic phosphorus metabolism remain unclear.
We have previously developed noninvasive 31 P magnet resonance spectroscopy (MRS) techniques, allowing for exact quantification of hepatic 31 P metabolite concentrations in a clinical setting (11, 12) . With the use of these methods, we now aimed at identifying metabolic determinants of hepatic g-ATP (gATP) and P i under physiological conditions in a cohort of middle-aged metabolically healthy volunteers.
Participants and Methods

Study population
The study was performed as a feasibility study in the context of the national cohort; its protocol is in line with the Declaration of Helsinki (version 2008) and approved by the Ethics Board of the Bavarian Medical Association and of the Heinrich-Heine University Düsseldorf. All participants gave their written, informed consent before inclusion into the study. From the general population with residency in the Düsseldorf region, 496 persons, aged 20 to 70 years, were recruited from July 2011 to December 2012 by advertisement or via local residents' registration office (Supplemental Fig. S1 ). Of those, 270 persons without known diabetes mellitus underwent an extended examination, including standardized interview, anthropometry, and blood sampling, after 10 hours fast, as well as a 75-g oral glucose tolerance test (OGTT). Magnetic resonance imaging and MRS were performed in 120 of these individuals. Parts of these data have already been published (11, 13) .
Clinical examination
Anthropometric data were measured, as reported previously (14) .
OGTT
A standardized 75-g OGTT (ACCU-CHECK ® Dextro O.G.T.; Roche, Basel, Switzerland) was performed after 10 hours overnight fasting with blood sampling, before and 30, 60, and 120 minutes after start. Dysglycemia was classified according to criteria of the American Diabetes Association.
Laboratory measurements
Measurements of glucose, alanine aminotransferase, aspartate aminotransferase, g-glutamyl transpeptidase, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglyceride, insulin, and C-peptide were performed, as reported previously (14) . Hemoglobin A1c was determined on a VARI-ANT-II TM Analyzer (Bio-Rad Laboratories, Munich, Germany). Plasma NEFAs were determined using the NEFA-HR kit (Wako Chemicals, Neuss, Germany).
Metabolome analyses
Sodium-heparinate plasma samples were rapidly frozen and stored at 280°C. Targeted metabolic profiling of 294 blood metabolites was performed with the X MetaDis/DQTM kit at Biocrates Life Sciences (Innsbruck, Austria) (13) . Fatty acid C18:0 was excluded from further analyses because of analytical errors. BCAAs were defined by the sum of isoleucine, leucine, and valine and d-9-desaturase (D9D) index by the ratio of palmitoleic and palmitic acid (13) .
Magnetic resonance imaging and MRS
All examinations were performed on a clinical 3-Tesla whole-body magnet (X-series Achieva; Philips, Best, The Netherlands), equipped with a 16-channel Torso XL phasedarray receiver coil for 1 H MRS and a 14-cm circular 31 P surface coil (transmit-receive coil) using standardized procedures, as described (11) . Liver triglyceride concentration [hepatocellular lipid content (HCL)] was assessed by 1 H MRS using the single voxel-stimulated echo acquisition mode (14) ; fat fraction was calculated as percentage of the ratio of lipids/(water + lipids), as described (11) . For liver 31 P MRS, scout images were taken with the 1 H body coil in three orientations, followed by transverse T2-weighted images with multislice two-dimensional spin echo images and respiratory triggering to identify liver position clearly and place the volume of interest (6 3 6 3 6 cm) within the liver, avoiding skeletal muscle. Localized liver spectra were obtained using image-selected spectroscopy, with specifications, and analyzed as described before (11) .
Measures of insulin sensitivity
From glucose, insulin, and C-peptide values, obtained during the OGTT, the following indices have been calculated for insulin sensitivity: oral glucose insulin-sensitivity index (OGIS), representing total glucose clearance or whole-body dynamic insulin sensitivity (15) , and quantitative insulin-sensitivity check index (QUICKI) to assess fasting (hepatic) insulin sensitivity, calculated as 1/[log(G0) + log(I0)], where G0 and I0 are fasting glucose and insulin, respectively (16) . The hepatic insulin resistance index (17) (19) . De novo lipogenesis (DNL) was calculated as reported previously (13) .
Statistical analyses
Normally distributed parameters are presented as means 6 standard deviation and skewed distributed parameters as median (interquartile range). Pearson correlation analyses were performed for the dependent variables gATP and P i . To account for potential confounders, such as age, sex, and BMI, partial (adjusted) Pearson correlations were calculated also. To improve normality, skewed distributed data were natural log transformed before analyses, as indicated (see Tables 1, 2 , and 3). P , 0.05 was considered to indicate statistically significant differences. The main analyses (associations between hepatic gATP or P i with markers of insulin resistance/amino acids/fatty acids) were adjusted for multiple testing using the Bonferroni method, as indicated in the respective table footnotes. Missing data were excluded from the analyses. No imputation methods were performed. Analyses were done using SAS Version 9.4 (SAS Institute, Cary, NC).
Results
Study population
Of 120 volunteers undergoing OGTT and MRS examinations, 76 entered the final analysis after exclusion of participants with missing measures and/or metabolic disease (Supplemental Fig. S1 ). Participants (26 men, 50 women) were middle aged (54 6 13 years), nonobese (BMI 24. Correlation analyses for hepatic phosphorus metabolites with glycemia and insulin sensitivity Pearson correlation analyses revealed positive relationships of hepatic gATP concentrations with 2-hour OGTT glucose and of P i with 2-hour OGTT glucose and NEFA, respectively ( Fig. 1A-1D ; Table 1 ). After adjustment for age, sex, and BMI, 2-hour OGTT glucose still related to both gATP and P i content and NEFA levels to P i concentrations. The adjustment of the analyses for P i or gATP abolished these associations, pointing to the impact of the concentration of the respective other phosphorus metabolite on these relationships (Table 1) . No associations with gATP or P i content were found for any calculated measure of insulin sensitivity in unadjusted and adjusted analyses ( Table 1) . No association remained statistically significant after correction for multiple testing.
Correlation analyses for hepatic phosphorus metabolites with amino acids
Hepatic gATP was positively associated with plasma leucine (Fig. 1E ) and ornithine. Hepatic P i related negatively to threonine (Table 2) . After adjustment for age, sex, and BMI, gATP still positively correlated with leucine and ornithine. Moreover, gATP associated with isoleucine, tryptophan, and BCAAs. The association of P i with threonine disappeared after adjustment for age, sex, and BMI (Table 2) . After additional adjustment for P i , the correlation of gATP with isoleucine, leucine, ornithine, tryptophane, and BCAA remained, whereas additional correlations of gATP with tyrosine and phenylalanine were found (Table 2) . After correction for multiple testing, only the association between gATP and leucine remained statistically significant (Table 2) .
Correlation analyses for hepatic phosphorus metabolites with fatty acids species
Neither gATP nor P i related to any analyzed saturated fatty acid species. Furthermore, gATP did not associate with any unsaturated fatty acid species (Table 3) . P i related positively to myristoleic acid (cC14:1w5), cC16: 1w5, palmitoleic acid (cC16:1w7; Fig. 1F ), adrenic acid (cC22:4w6), and the D9D index.
After adjustment for age, sex, and BMI, only the relationships of P i with myristoleic acid, cC16:1w5, palmitoleic acid, and D9D index remained (Table 3 ). Further adjustment for P i revealed negative relationships of gATP with cC16:1w5 and adrenic acid. After adjustment for gATP, P i related positively to myristoleic acid, cC16:1w5, palmitoleic acid, adrenic acid, and D9D index (Table 3) . When corrected for multiple testing, none of the associations remained statistically significant (Table 3) . In multivariate regression models, age, sex, and BMI explained 9.8% of gATP and 7.8% of P i variability, respectively. Additional adjustment for leucine, as a significant independent predictor, explained 26% of gATP variances, and the adjustment for age, sex, BMI, and palmitoleic acid accounted for 15% of P i variability. A multivariate regression analysis containing variables age, sex, BMI, palmitoleic acid, and cC16:1w5 did not improve R 2 (0.16).
Predictors of hepatic phosphorus metabolite concentrations
These analyses identified leucine and C16:1 fatty acid palmitoleic acid as predictors of gATP and P i content, respectively. We further confirmed that additional adjustment for selected parameters, indicative of insulin resistance and glucose intolerance, did not affect these relationships (Supplemental Table S3 ). The close association of gATP and leucine was not affected by adjustment for any of the chosen parameters. However, the relation of P i and palmitoleic acid disappeared by adjustment for 2-hour OGTT glucose and NEFA levels, respectively. 
Discussion
This study found that specific essential amino acids and fatty acid species are independent predictors of hepatic gATP and P i content in metabolically healthy humans, whereas measures of insulin sensitivity neither related to hepatic gATP nor to P i content. This cohort had low HCL, normal glucose tolerance, and insulin sensitivity, based on the OGTT analysis (15) . Moreover, absolute concentrations of hepatic gATP and P i were similar to nondiabetic cohorts with comparable baseline characteristics (2, 12) . Thus, this cohort represents an appropriate group for investigation of hepatic energy status under physiological conditions. Absolute hepatic concentrations of P i and ATP have been reported to be positively associated with hepatic but not with peripheral insulin sensitivity and negatively with HCL in a mixed collective of patients with T2D and nondiabetic humans (2) . Another study reported a negative correlation of ATP levels with BMI (20) . Of note, our results do not confirm these associations in a collective of nondiabetic humans, as we did not observe any association of gATP and P i with indices of fasting (QUICKI), dynamic peripheral (OGIS), or hepatic (Hepatic-IR index, relationship between insulin sensitivity and cardiovascular disease) and adipose tissue (Adipo-IR index) insulin sensitivity, HCL, or BMI, respectively. This might result from the fact that our collective excluded participants with hyperglycemia or hepatic steatosis. Furthermore, we used fasting and OGTT-derived measures of insulin sensitivity, but OGIS and M-values calculated from OGTT and hyperinsulinemic-euglycemic clamps, respectively, are closely correlated (7, 15) .
Unexpectedly, we observed a positive relationship of both gATP and P i with 2-hour OGTT glucose levels, which may serve as a rough predictor of insulin resistance (21) . However, factors other than insulin resistance, such as duration of fasting and the amount of carbohydrate intake on the previous days, may influence OGTT glucose levels (22, 23) . In T2D, the negative relationship between hepatic gATP and ATP synthase flux and insulin resistance was determined, at least in part, by fasting plasma glucose and hemoglobin A1c, respectively (2, 3) . Thus, the observed positive relationships of hepatic gATP and P i with 2-hour OGTT glucose observed in this nonobese nondiabetic cohort are unlikely a result of insulin resistance. Of note, nondiabetic but obese persons even show greater hepatic oxidative capacity, despite peripheral insulin resistance (1).
We found a positive relation of P i with circulating NEFA. In patients with T2D, no correlation was found for ATP flux and NEFA (3). Previous studies reported no association of gATP and plasma NEFA levels in metabolically healthy and diseased humans (12, 24) , whereas P i associated negatively with NEFA levels in a combined collective of healthy, obese, and T2D volunteers (12) . Moreover, P i did not correlate with the Adipo-IR index, suggesting that Adipo-IR cannot exclusively explain the relationship of P i and NEFA. However, a discrete effect cannot be resolved by our study as a result of the limited sample size. Thus, in healthy humans with intact metabolic flexibility, higher substrate availability of either glucose or NEFA may charge hepatic phosphorus pools and/or stimulate energy-generating processes (25) . Of note, further adjustment for gATP or P i , respectively, abolished the previous associations, indicating that the relationship of 2-hour OGTT glucose with gATP and P i , as well as of NEFA concentrations with P i , also depends on the prevailing P i and gATP levels, respectively. Absolute fasting gATP and P i levels, as well as P i /ATP ratios of our study, differed, in part, from those of the respective studies, which might also explain the observed differences in the correlation analyses (2, 3, 12) . However, none of the associations of gATP or P i with 2-hour OGTT glucose and of NEFA concentrations with P i was statistically significant when corrected for multiple testing.
Interestingly, this study found a positive association of gATP with some essential amino acids and of P i with some fatty acid species, respectively. People with insulin resistance or T2D typically present with higher levels of combined BCAA (leucine, isoleucine, valine) and/or other amino acids (phenylalanine, tryptophane, tyrosine, alanine, citrulline) and lower levels of threonine, glycine, and glutamine (9, 13) . In our metabolically healthy cohort, gATP related strongest to leucine, independent of changes in P i content. Leucine and isoleucine were reported to be elevated in obese compared with lean humans (9) . In our cohort, gATP still related closely to leucine even after adjustment for age, sex, and BMI. Further investigation of parameters affecting the relation of gATP and leucine showed no effect on this interaction.
In obese mice, leucine increases ATP concentrations in brown adipose tissue as a result of stimulation of mitochondrial biogenesis (26) , and in skeletal muscle cells, leucine stimulates fatty acid oxidation, as well as oxygen consumption (27) . Moreover, leucine provides carbon skeletons to the tricarboxylic acid (TCA) cycle at the level of acetyl-coenzyme A, which may enhance TCA cycle flux (28) . Thus, higher plasma leucine levels likely contribute to improved mitochondrial performance rather than reflect insulin resistance or impaired mitochondrial function in our collective of healthy humans.
This study observed relevant correlations of P i with unsaturated fatty acid species, such as myristoleic acid, C16:1w5, palmitoleic acid, and adrenic acid. The absolute concentrations of these fatty acids were rather low, as previously reported (29) . Whereas our assay does not distinguish between cis and trans fatty acids, the low contribution of trans fatty acids to the total circulating fatty acid pool, amounting to ,2% (30) , suggests that the observed correlations are mainly driven by the respective cis isomers. Myristoleic acid usually accounts for only small amounts of total fatty acids in animal tissues but is abundant in milk fat and may also raise palmitoleic acid levels (31) . It is therefore conceivable that the circulating palmitoleic and myristoleic acid levels, at least partly, result from dietary intake.
We did not detect a correlation of the DNL index and gATP or P i , respectively. The main fatty acid products of DNL include palmitic acid, palmitoleic acid, vaccenic acid, stearic acid, and oleic acid (32) . Except for palmitoleic acid, we did not find a correlation of those fatty acids with P i , further suggesting that the relationship of P i and palmitoleic acid does not result from DNL. Nevertheless, palmitoleic acid per se and the D9D index have been proposed as markers of DNL (33) .
The strong interaction between P i and palmitoleic acid disappeared upon adjustments for fasting NEFA and 2-hour OGTT glucose levels. Fasting NEFA levels mainly reflect adipose tissue lipolysis, which also is tightly regulated by the glucose-regulating hormones insulin and catecholamines (34) . This suggests that both NEFA supply to the liver and regulatory hormones contribute to this interaction. Palmitoleic acid has originally gained attention as an anti-inflammatory adipokine (35) . In a murine model, chronic palmitoleic acid feeding enhances hepatic glucose uptake and fatty acid oxidation for energy production instead of storage through activation of adenosine 5 0 -monophosphate-activated protein kinase and fibroblast growth factor 21 -21, dependent on peroxisome proliferator-activated receptor a (10). Of note, cis monounsaturated fatty acids also strongly inhibit Ca 2+ uptake, thereby inducing net Ca 2+ efflux and higher extramitochondrial Ca 2+ concentrations (36) . Effects of palmitoleic acid and its ester on mitochondrial metabolism have also been reported in other tissues (37) . Taken together, these relationships of palmitoleic and myristoleic acids with hepatic P i might result directly or indirectly from their interaction with mitochondrial Ca 2+ handling and reduction in the mitochondrial membrane potential. As to possible hepatic effects of the other unsaturated fatty acids, adrenic acid may act as an inflammation enhancer in NAFLD (38) , whereas there is currently no information on the physiological relevance of C16:1w5.
The strength of this study is the investigation of hepatic energy metabolism in a larger cohort of well-phenotyped, glucose-tolerant humans. Up until now, hepatic ATP and P i content have mainly been studied in the context of metabolic diseases, such as T2D or NAFLD (2, 3, 6) . This approach might help to differentiate among factors regulating ATP and P i in nondiabetic, nonobese, non-NAFLD persons and in those with metabolic disease. This study also has some limitations. The main weakness resides in the inclusion of only healthy, nonobese individuals. Nevertheless, relationships of amino and fatty acid species with hepatic phosphorus metabolites have, to our knowledge, not been reported before, and this study provides that information.
Although measurement of absolute hepatic concentrations of ATP and P i is reliable and highly reproducible, it covers only one aspect of hepatic energy metabolism-the flux through hepatic ATP synthase (3)-but does not address other features of mitochondrial function, such as TCA cycle activity and oxidative capacity, which may be differently affected in health and disease (1, 39, 40) . Furthermore, the observed effect of leucine and palmitoleic acid on ATP and P i levels is only modest, implying that other factors also regulate hepatic energy metabolism in healthy humans. Such factors might be less relevant in the presence of hepatic steatosis, insulin resistance, or hepatocellular injury (2, 6) . Our data, from the examined cohort, suggest that hepatic concentrations of ATP and P i relate to specific circulating amino acids and fatty acid species, but analyses could be considered exploratory as a result of the size of our cohort and the lack of statistical significance after Bonferroni correction for many associations. However, the strongest correlation found for hepatic gATP levels with leucine was still present after correction for multiple testing.
In conclusion, hepatic gATP and P i do not relate to measures of insulin sensitivity in metabolically healthy nonobese humans. However, specific circulating amino acids and NEFAs partly affect the availability of hepatic phosphorus metabolites. These results point to a mutual interaction between hepatic energy metabolism and circulating metabolites and may therefore contribute to the better understanding of the differences in hepatic energy metabolism between glucose-tolerant and insulinresistant humans.
